- Home
- LICN vs OPTN Comparison
LICN vs OPTN Comparison
Compare LICN & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LICN
- OPTN
- Stock Information
- Founded
- LICN 2004
- OPTN 2010
- Country
- LICN China
- OPTN United States
- Employees
- LICN N/A
- OPTN N/A
- Industry
- LICN
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- LICN
- OPTN Health Care
- Exchange
- LICN Nasdaq
- OPTN Nasdaq
- Market Cap
- LICN 83.8M
- OPTN 99.7M
- IPO Year
- LICN 2023
- OPTN 2017
- Fundamental
- Price
- LICN $1.82
- OPTN $0.46
- Analyst Decision
- LICN
- OPTN Strong Buy
- Analyst Count
- LICN 0
- OPTN 3
- Target Price
- LICN N/A
- OPTN $3.00
- AVG Volume (30 Days)
- LICN 612.3K
- OPTN 617.5K
- Earning Date
- LICN 11-26-2024
- OPTN 11-12-2024
- Dividend Yield
- LICN N/A
- OPTN N/A
- EPS Growth
- LICN 36.90
- OPTN N/A
- EPS
- LICN 0.28
- OPTN N/A
- Revenue
- LICN $41,929,000.00
- OPTN $75,672,000.00
- Revenue This Year
- LICN N/A
- OPTN $24.44
- Revenue Next Year
- LICN N/A
- OPTN $49.00
- P/E Ratio
- LICN $6.57
- OPTN N/A
- Revenue Growth
- LICN 24.86
- OPTN 5.13
- 52 Week Low
- LICN $0.50
- OPTN $0.44
- 52 Week High
- LICN $2.44
- OPTN $2.10
- Technical
- Relative Strength Index (RSI)
- LICN 43.65
- OPTN 28.38
- Support Level
- LICN $1.96
- OPTN $0.50
- Resistance Level
- LICN $2.31
- OPTN $0.81
- Average True Range (ATR)
- LICN 0.20
- OPTN 0.06
- MACD
- LICN -0.00
- OPTN -0.02
- Stochastic Oscillator
- LICN 16.67
- OPTN 3.23
About LICN Lichen China Limited
Lichen China Ltd is a holding company. The company, along with its subsidiaries provides financial and taxation solution services; education support services; and software and maintenance services. The company generates Majority revenue from Financial and taxation solution services.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.